14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
The long-awaited revision of the Form I-9 was released by the U.S. Citizenship and Immigration Servi...
Read More >
The U.S. Department of Labor (DOL) issued two Fair Labor Standards Act (FLSA) opinion letters on Jan...
Read More >
From environmental risks and shifting OSHA regulations to community engagement and emerging workplac...
Read More >
Daily headlines about the growing coronavirus threat have many employers concerned that they are not...
Read More >
The latest version of Assembly Bill 5, which codifies the California Supreme Court’s Dynamex decisi...
Read More >
Employers are not permitted to justify disparity in pay based on prior pay history, the 9th Circuit ...
Read More >